DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapidconstrictive pericarditisright heart failurepericardiectomyseptal bouncerestrictive cardiomyopathy

Constrictive pericarditis

Essential points for quick revision.

!
Escalate

Rapidly worsening low output, severe congestion with renal/hepatic failure, or diagnostic concern for effusive-constrictive tamponade requires urgent admission and specialist haemodynamic assessment.

Synopsis

Distinguish potentially curable pericardial constriction from restrictive myocardium, identify transient inflammation and refer fixed disease for timely pericardiectomy.

  • Constrictive pericarditis is impaired diastolic filling from a non-compliant pericardium and is a potentially curable cause of predominantly right-sided HF.
  • Clues are raised JVP, prominent y descent, Kussmaul sign, pericardial knock, ascites and oedema with relatively clear lungs.
  • Echo looks for ventricular interdependence: septal bounce, respiratory mitral/tricuspid inflow variation and expiratory hepatic-vein diastolic reversal.

Key red flags

Advanced disease

Hypotension, hyponatraemia, renal dysfunction, jaundice/cardiac cirrhosis, severe hypoalbuminaemia or cachexia signals high operative risk and urgent referral.

Investigation priorities

01
Comprehensive Doppler TTEFirst step

Demonstrate interdependence and distinguish constriction from restriction.

Management branches

DiagnosisSuspected constrictive physiology

Unexplained right HF/HFpEF with pericardial risk or JVP signs.

  1. Obtain expert Doppler echo and review prior surgery, radiation, pericarditis, TB and malignancy; assess liver/renal/nutritional status.
  2. Use CT for thickness/calcification and CMR for inflammation, interdependence and myocardial differential.

Key medicines

FurosemideCommon oral starting dose 20-40 mg once daily, titrated cautiously to congestion.
Ibuprofen600 mg orally three times daily for active inflammatory constriction, then taper after clinical and CRP remission; maximum 2400 mg/day.
Open full textbook Answer 2 questionsCardiology check
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom